Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ

Stock Track

02-24

Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.

The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.

Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1117228916"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117228916\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1117228916?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117228916","market":"hk","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ","media":"Stock Track","content":"<p>Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.</p>\n\n<p>The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.</p>\n\n<p>Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-24 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.</p>\n\n<p>The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.</p>\n\n<p>Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1117228916","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117228916","pubTimestamp":1740404546,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics  shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics因与PATHOMIQ达成许可协议而盘前暴跌6.56%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.\nThe deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.\nMyriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}